EASL Journal Club: Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

This EASL Journal Club will discuss the paper "Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab" presenting the results of the “French Medicine Genomic program 2025”.